Bioelectrix is developing a new medical device to actively accelerate wound healing. The technology itself is important, but in wound care, strong technology is not enough.
For a solution to be adopted at scale, it must also prove that it reduces the total burden on healthcare systems. That means showing, in a credible and structured way, that improved healing translates into real-world savings: fewer clinic visits, less staff time, fewer dressing changes, fewer complications, and fewer escalations to higher-cost care. In other words, better outcomes must be linked to lower or more efficient costs and that link has to be measured, not assumed.
Why this matters commercially
Wound care sits at the intersection of clinical outcomes and resource intensity. Chronic wounds can require repeated follow-ups over long periods, often involving multidisciplinary care and expensive consumables. Even if a new device improves healing, decision makers will still ask:
- Does this reduce workload in clinics, or does it add steps?
- Will it lower the number of visits and interventions over time?
- Does it prevent costly complications that drive hospital use?
- How does the total cost compare to current standard pathways?
- What evidence will we be able to show at procurement and reimbursement decision points?
These questions are not just academic, they are central to market access. Without a clear health economic case, even clinically effective innovations can struggle to move from pilot use to routine practice.
Ahinsa’s contribution
Over the last three months, Ahinsa has helped Bioelectrix strengthen this foundation by delivering a health economics report and a flexible modelling framework that can be expanded as more data becomes available.
The purpose of the work is straightforward: ensure Bioelectrix can demonstrate value in the language healthcare systems use to make adoption decisions — outcomes plus cost impact — and do it early enough that our evidence generation is aligned with what payers, procurement teams, and clinical leaders will need to see.
Focus markets: Germany, Sweden, and Spain
This work is particularly relevant for Bioelectrix’s initial market focus in Germany, Sweden, and Spain, where adoption and scale depend on combining clinical evidence with a credible value story. Building a structured economic case early helps us avoid a common trap in medtech: generating promising clinical results that do not map cleanly to purchasing and reimbursement decisions.
What comes next
The framework is designed to be built on as new inputs arrive in March, allowing the economic case to mature in step with our technical and clinical progress. As we generate additional evidence, the model can be updated to reflect real-world assumptions and strengthen the credibility of the savings story.
Thank you, Ahinsa!
We are grateful for Ahinsa’s contribution to Bioelectrix and wish her the very best of luck as she continues her work in Australia.
